Skip to main content

Michael Roger Harrison

Associate Professor of Medicine
Medicine, Medical Oncology

Current Appointments & Affiliations


Associate Professor of Medicine · 2021 - Present Medicine, Medical Oncology, Medicine
Member of the Duke Cancer Institute · 2011 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.

Journal Article Eur Urol Oncol · April 2025 BACKGROUND AND OBJECTIVE: Androgen deprivation therapy (ADT) with salvage radiation therapy (RT) improves survival for patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) for prostate cancer (PC), but many patients suf ... Full text Link to item Cite

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy.

Journal Article JCI Insight · January 7, 2025 Since multiple front-line immune checkpoint inhibitor-based (ICI-based) combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical prognostication scores and transcriptome gene expression ... Full text Link to item Cite

Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma.

Journal Article Eur Urol Open Sci · August 2024 INTRODUCTION AND HYPOTHESES: The Outcomes Database to prospectivelY aSSEss the changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC) Registry is a large, nationally representative prospective registry of patients with metastatic renal cell carci ... Full text Link to item Cite
View All Publications

Recent Grants


DoD: PCRP Clinical Consortium: Duke University Clinical Research Site

ResearchCo Investigator · Awarded by Department of Defense · 2007 - 2026

Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer PRL-02

Clinical TrialPrincipal Investigator · Awarded by Propella Therapeutics Inc · 2022 - 2026

View All Grants

Education, Training & Certifications


Tulane University · 2004 M.D.